Omalizumab is associated with improved asthma outcomes in children and adolescents with serum immunoglobulin E above dosing guidelines is a research paper published in The Journal of Allergy and Clinical Immunology In Practice (2022). On theSindex it has a DataRank of 0. It has been cited 4 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Heart, Lung, and Blood Institute
Grant: R01HL135235
National Institute of Allergy and Infectious Diseases
Grant: T32AI007062
National Center for Advancing Translational Sciences
Grant: KL2TR002490
National Center for Advancing Translational Sciences
Grant: UL1TR002489
National Institutes of Health
Grant: 3UL1TR002489-02S1
North Carolina Translational and Clinical Science Institute (NC TraCS)
National Institutes of Health
Grant: 5KL2TR002490-05
North Carolina Translational and Clinical Science Institute (NC TraCS) KL2
National Institutes of Health
Grant: 5T32AI007062-42
Research Training in Allergy and Clinical Immunology
National Institutes of Health
Grant: 1R01HL135235-01A1
IL-1 receptor blockade as a novel treatment for exacerbation of allergic airway responses in humans
Fields of Study
Keywords